靶向CD70的cusatuzumab联合去甲基化药物清除急性髓系白血病干细胞
急性髓系白血病干细胞对常规化疗耐药是复发主因,去甲基化药物(HMA)疗效有限。本研究发现HMA上调白血病干细胞CD70表达,增强CD70/CD27信号;人源抗CD70单抗cusatuzumab通过增强抗体依赖细胞毒作用在体外和异种移植中清除白血病干细胞。1/2期试验中,12例初治老年AML患者接受cusatuzumab单药后联合阿扎胞苷,8例完全缓解、2例血液学未完全恢复的完全缓解、2例部分缓解,4例流式检测微小残留病阴性(<10^-3)。
要点
- HMA治疗上调白血病干细胞CD70表达并增强CD70/CD27信号。
- cusatuzumab在体外及异种移植中清除表达CD70的白血病干细胞。
- 1/2期试验中cusatuzumab联合阿扎胞苷在初治老年AML显示血液学缓解。
核心结论
- cusatuzumab靶向表达CD70的白血病干细胞,联合阿扎胞苷在初治老年AML患者中诱导血液学缓解。
研究设计与样本
- 临床前研究结合1/2期试验(NCT03030612),报告1期剂量递增部分。
- 入组12例既往未治疗的老年AML患者,接受单剂cusatuzumab后联合阿扎胞苷。
主要发现
- 12例中8例完全缓解、2例血液学未完全恢复的完全缓解、2例部分缓解。
- 4例通过流式细胞术达到微小残留病阴性(<10^-3)。
- 中位起效时间3.3个月,数据截止时中位无进展生存期未达到。
- 未报告剂量限制性毒性,未达到最大耐受剂量。
- cusatuzumab治疗显著减少白血病干细胞并触发髓系分化和凋亡相关基因签名。
关键数值与推荐
- 微小残留病阴性定义为流式细胞术检测<10^-3。
- 临床前显示HMA上调白血病干细胞CD70表达并增强CD70/CD27信号。
临床怎么用
- 初治老年AML患者可考虑cusatuzumab单药后联合阿扎胞苷治疗。
- 治疗中需监测血液学缓解及微小残留病(流式细胞术<10^-3)。
局限性
- 报告限于1期剂量递增部分的小样本(12例)。
- 中位无进展生存期数据截止时未达到,长期疗效待随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs) that resist conventional chemotherapy and are the major cause of relapse1,2. Hypomethylating agents (HMAs) are the standard of care in the treatment of older or unfit patients with AML, but responses are modest and not durable3-5. Here we demonstrate that LSCs upregulate the tumor necrosis factor family ligand CD70 in response to HMA treatment resulting in increased CD70/CD27 signaling. Blocking CD70/CD27 signaling and targeting CD70-expressing LSCs with cusatuzumab, a human αCD70 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity activity, eliminated LSCs in vitro and in xenotransplantation experiments. Based on these preclinical results, we performed a phase 1/2 trial in previously untreated older patients with AML with a single dose of cusatuzumab monotherapy followed by a combination therapy with the HMA azacitidine ( NCT03030612 ). We report results from the phase 1 dose escalation part of the clinical trial. Hematological responses in the 12 patients enrolled included 8 complete remission, 2 complete remission with incomplete blood count recovery and 2 partial remission with 4 patients achieving minimal residual disease negativity by flow cytometry at <10-3. Median time to response was 3.3 months. Median progression-free survival was not reached yet at the time of the data cutoff. No dose-limiting toxicities were reported and the maximum tolerated dose of cusatuzumab was not reached. Importantly, cusatuzumab treatment substantially reduced LSCs and triggered gene signatures related to myeloid differentiation and apoptosis.
引用
- Riether C, Pabst T, Höpner S, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020. PMID: 32601337. doi:10.1038/s41591-020-0910-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。